Symbols / TBIO $0.06 +0.00% Telesis Bio, Inc.
TBIO Chart
About
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It has license agreement with Regeneron Pharmaceuticals, Inc. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 97.67K |
| Enterprise Value | 42.96M | Income | -47.45M | Sales | 17.03M |
| Book/sh | -15.35 | Cash/sh | 2.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 39 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | 0.01 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -1.50 | EV/Sales | 2.52 | Quick Ratio | 0.87 |
| Current Ratio | 1.23 | Debt/Eq | 420.52 | LT Debt/Eq | — |
| EPS (ttm) | -30.42 | EPS next Y | -18.89 | EPS Growth | — |
| Revenue Growth | -61.80% | Earnings | 2025-06-11 16:00 | ROA | -30.10% |
| ROE | -178.99% | ROIC | — | Gross Margin | 46.87% |
| Oper. Margin | -3.28% | Profit Margin | -267.41% | Shs Outstand | 1.78M |
| Shs Float | 1.24M | Short Float | 7.31% | Short Ratio | 0.42 |
| Short Interest | — | 52W High | 1.55 | 52W Low | 0.00 |
| Beta | 2.50 | Avg Volume | 128.00 | Volume | 3.00 |
| Target Price | — | Recom | None | Prev Close | $0.06 |
| Price | $0.06 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.06
Latest analyst target
3. DCF / Fair value
$-103.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.06
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-11 | down | Keybanc | Overweight → Sector Weight | — |
- Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena hu, 12 Feb 2026 08
- William Blair reiterates Outperform on Cabaletta Bio stock - Investing.com Mon, 23 Mar 2026 07
- Tevogen Bio Stock Pre-Market (-7.0%): 1-for-50 Reverse Split Becomes Effective - Trefis Sat, 07 Mar 2026 08
- Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance hu, 26 Feb 2026 08
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy - The Motley Fool ue, 03 Mar 2026 08
- Cabaletta Bio Stock (CABA) Opinions on Insider Buying and Clinical Updates | CABA Stock News - Quiver Quantitative Fri, 23 Jan 2026 08
- Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits Mon, 23 Feb 2026 16
- Guggenheim cuts Adicet Bio stock price target to $100 on valuation - Investing.com Fri, 13 Mar 2026 07
- Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data - Trefis Wed, 11 Feb 2026 08
- Positive Signs As Multiple Insiders Buy TELA Bio Stock - Yahoo Finance hu, 09 Oct 2025 07
- Why Belite Bio Stock Soared on Monday - The Motley Fool Mon, 01 Dec 2025 08
- Leerink reiterates Market Perform on Boundless Bio stock at $4 - Investing.com ue, 10 Mar 2026 07
- What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance Fri, 30 Jan 2026 08
- Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis Fri, 06 Mar 2026 08
- Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com Wed, 11 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
27.51
+0.27%
|
27.43
+148.44%
|
11.04
|
| Operating Revenue |
|
27.51
+0.27%
|
27.43
+148.44%
|
11.04
|
| Cost Of Revenue |
|
10.56
-10.82%
|
11.84
+75.56%
|
6.74
|
| Reconciled Cost Of Revenue |
|
10.56
-10.82%
|
11.84
+75.56%
|
6.74
|
| Gross Profit |
|
16.95
+8.69%
|
15.60
+262.76%
|
4.30
|
| Operating Expense |
|
52.10
-16.08%
|
62.08
+56.48%
|
39.67
|
| Research And Development |
|
17.50
-25.42%
|
23.46
+62.17%
|
14.47
|
| Selling General And Administration |
|
34.60
-10.40%
|
38.62
+53.21%
|
25.21
|
| Selling And Marketing Expense |
|
13.51
-18.04%
|
16.49
+50.47%
|
10.96
|
| General And Administrative Expense |
|
21.09
-4.70%
|
22.13
+55.32%
|
14.25
|
| Other Gand A |
|
21.09
-4.70%
|
22.13
+55.32%
|
14.25
|
| Total Expenses |
|
62.66
-15.23%
|
73.92
+59.25%
|
46.42
|
| Operating Income |
|
-35.15
+24.38%
|
-46.48
-31.41%
|
-35.37
|
| Total Operating Income As Reported |
|
-46.54
-0.12%
|
-46.48
-31.41%
|
-35.37
|
| EBITDA |
|
-40.49
+7.16%
|
-43.62
-21.15%
|
-36.00
|
| Normalized EBITDA |
|
-29.43
+31.38%
|
-42.90
-26.68%
|
-33.86
|
| Reconciled Depreciation |
|
4.10
+42.68%
|
2.88
+82.66%
|
1.57
|
| EBIT |
|
-44.59
+4.08%
|
-46.49
-23.73%
|
-37.58
|
| Total Unusual Items |
|
-11.06
-1437.97%
|
-0.72
+66.39%
|
-2.14
|
| Total Unusual Items Excluding Goodwill |
|
-11.06
-1437.97%
|
-0.72
+66.39%
|
-2.14
|
| Special Income Charges |
|
-11.39
-1466.57%
|
-0.73
-17.64%
|
-0.62
|
| Other Special Charges |
|
—
|
0.73
+17.64%
|
0.62
|
| Impairment Of Capital Assets |
|
11.39
|
0.00
|
—
|
| Net Income |
|
-47.72
+1.54%
|
-48.47
-24.42%
|
-38.96
|
| Pretax Income |
|
-47.70
+1.54%
|
-48.45
-24.40%
|
-38.94
|
| Net Non Operating Interest Income Expense |
|
-1.36
-11.91%
|
-1.22
+11.10%
|
-1.37
|
| Interest Expense Non Operating |
|
3.10
+58.82%
|
1.96
+42.80%
|
1.37
|
| Net Interest Income |
|
-1.36
-11.91%
|
-1.22
+11.10%
|
-1.37
|
| Interest Expense |
|
3.10
+58.82%
|
1.96
+42.80%
|
1.37
|
| Interest Income Non Operating |
|
1.74
+136.18%
|
0.74
|
—
|
| Interest Income |
|
1.74
+136.18%
|
0.74
|
—
|
| Other Income Expense |
|
-11.19
-1401.74%
|
-0.74
+66.15%
|
-2.20
|
| Other Non Operating Income Expenses |
|
-0.13
-400.00%
|
-0.03
+58.06%
|
-0.06
|
| Gain On Sale Of Security |
|
0.33
+4037.50%
|
0.01
+100.53%
|
-1.52
|
| Tax Provision |
|
0.02
+0.00%
|
0.02
+71.43%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
-22.22%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-2.32
-1437.97%
|
-0.15
+73.86%
|
-0.58
|
| Net Income Including Noncontrolling Interests |
|
-47.72
+1.54%
|
-48.47
-24.42%
|
-38.96
|
| Net Income From Continuing Operation Net Minority Interest |
|
-47.72
+1.54%
|
-48.47
-24.42%
|
-38.96
|
| Net Income From Continuing And Discontinued Operation |
|
-47.72
+1.54%
|
-48.47
-24.42%
|
-38.96
|
| Net Income Continuous Operations |
|
-47.72
+1.54%
|
-48.47
-24.42%
|
-38.96
|
| Normalized Income |
|
-38.99
+18.61%
|
-47.90
-28.09%
|
-37.40
|
| Net Income Common Stockholders |
|
-49.02
-1.14%
|
-48.47
-24.42%
|
-38.96
|
| Diluted EPS |
|
-29.52
+0.61%
|
-29.70
+22.90%
|
-38.52
|
| Basic EPS |
|
-29.52
+0.61%
|
-29.70
+22.90%
|
-38.52
|
| Basic Average Shares |
|
1.66
+1.31%
|
1.64
+61.69%
|
1.01
|
| Diluted Average Shares |
|
1.66
+1.31%
|
1.64
+61.69%
|
1.01
|
| Diluted NI Availto Com Stockholders |
|
-49.02
-1.14%
|
-48.47
-24.42%
|
-38.96
|
| Preferred Stock Dividends |
|
1.30
|
—
|
—
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets |
|
70.41
-13.46%
|
81.36
-30.02%
|
116.26
|
| Current Assets |
|
30.35
-44.91%
|
55.09
-40.88%
|
93.18
|
| Cash Cash Equivalents And Short Term Investments |
|
19.16
-56.04%
|
43.58
-47.37%
|
82.81
|
| Cash And Cash Equivalents |
|
1.57
-94.84%
|
30.42
-63.26%
|
82.81
|
| Other Short Term Investments |
|
17.59
+33.66%
|
13.16
|
0.00
|
| Receivables |
|
5.99
+2.29%
|
5.85
+59.65%
|
3.67
|
| Accounts Receivable |
|
5.99
+2.29%
|
5.85
+59.65%
|
3.67
|
| Gross Accounts Receivable |
|
7.27
+17.40%
|
6.19
+69.00%
|
3.67
|
| Allowance For Doubtful Accounts Receivable |
|
-1.29
-275.22%
|
-0.34
|
0.00
|
| Inventory |
|
4.03
+82.95%
|
2.20
-7.09%
|
2.37
|
| Raw Materials |
|
2.03
+94.06%
|
1.04
+8.52%
|
0.96
|
| Work In Process |
|
1.03
+59.35%
|
0.65
-27.79%
|
0.90
|
| Finished Goods |
|
0.97
+90.18%
|
0.51
-0.20%
|
0.51
|
| Prepaid Assets |
|
—
|
—
|
4.34
|
| Restricted Cash |
|
0.17
+0.00%
|
0.17
|
0.00
|
| Other Current Assets |
|
1.01
-69.34%
|
3.29
-24.33%
|
4.34
|
| Total Non Current Assets |
|
40.06
+52.49%
|
26.27
+13.86%
|
23.07
|
| Net PPE |
|
34.52
+305.12%
|
8.52
+48.53%
|
5.74
|
| Gross PPE |
|
37.99
+263.19%
|
10.46
+60.20%
|
6.53
|
| Accumulated Depreciation |
|
-3.47
-79.02%
|
-1.94
-144.64%
|
-0.79
|
| Properties |
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
9.86
+36.08%
|
7.24
+176.62%
|
2.62
|
| Construction In Progress |
|
0.59
-60.96%
|
1.50
-2.28%
|
1.54
|
| Other Properties |
|
27.22
+1539.76%
|
1.66
-27.22%
|
2.28
|
| Leases |
|
0.33
+472.41%
|
0.06
-38.95%
|
0.10
|
| Goodwill And Other Intangible Assets |
|
4.86
-70.99%
|
16.77
+0.25%
|
16.73
|
| Goodwill |
|
3.50
-76.51%
|
14.89
+3.88%
|
14.33
|
| Other Intangible Assets |
|
1.37
-27.36%
|
1.88
-21.49%
|
2.40
|
| Other Non Current Assets |
|
0.68
-31.09%
|
0.98
+61.08%
|
0.61
|
| Total Liabilities Net Minority Interest |
|
40.87
+17.46%
|
34.80
+36.60%
|
25.47
|
| Current Liabilities |
|
8.18
-39.37%
|
13.50
+38.68%
|
9.73
|
| Payables And Accrued Expenses |
|
5.93
-30.46%
|
8.53
+16.01%
|
7.35
|
| Payables |
|
3.28
+153.59%
|
1.29
-48.18%
|
2.50
|
| Accounts Payable |
|
3.28
+153.59%
|
1.29
-48.18%
|
2.50
|
| Current Accrued Expenses |
|
2.65
-63.40%
|
7.24
+49.05%
|
4.85
|
| Current Debt And Capital Lease Obligation |
|
1.82
+186.03%
|
0.64
-65.38%
|
1.84
|
| Current Debt |
|
—
|
—
|
0.60
|
| Other Current Borrowings |
|
—
|
—
|
0.60
|
| Current Capital Lease Obligation |
|
1.82
+186.03%
|
0.64
-48.50%
|
1.24
|
| Current Deferred Liabilities |
|
0.34
-91.46%
|
3.96
+1830.73%
|
0.20
|
| Current Deferred Revenue |
|
0.34
-91.46%
|
3.96
+1830.73%
|
0.20
|
| Other Current Liabilities |
|
0.09
-75.34%
|
0.37
+11.34%
|
0.34
|
| Total Non Current Liabilities Net Minority Interest |
|
32.69
+53.48%
|
21.30
+35.32%
|
15.74
|
| Long Term Debt And Capital Lease Obligation |
|
32.56
+56.60%
|
20.79
+34.28%
|
15.48
|
| Long Term Debt |
|
5.27
-73.18%
|
19.65
+39.47%
|
14.09
|
| Long Term Capital Lease Obligation |
|
27.29
+2291.67%
|
1.14
-18.15%
|
1.39
|
| Non Current Deferred Liabilities |
|
0.10
-33.10%
|
0.14
-5.33%
|
0.15
|
| Non Current Deferred Revenue |
|
0.10
-33.10%
|
0.14
-5.33%
|
0.15
|
| Stockholders Equity |
|
29.54
-36.57%
|
46.56
-48.71%
|
90.78
|
| Common Stock Equity |
|
0.24
-99.49%
|
46.56
-48.71%
|
90.78
|
| Capital Stock |
|
29.30
+586000.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
29.30
|
0.00
|
0.00
|
| Share Issued |
|
1.67
+1.40%
|
1.65
+1.12%
|
1.63
|
| Ordinary Shares Number |
|
1.67
+1.40%
|
1.65
+1.12%
|
1.63
|
| Additional Paid In Capital |
|
161.70
+0.87%
|
160.30
+2.73%
|
156.05
|
| Retained Earnings |
|
-161.47
-41.96%
|
-113.74
-74.26%
|
-65.27
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
+100.00%
|
-0.00
|
0.00
|
| Other Equity Adjustments |
|
—
|
-0.00
|
—
|
| Total Equity Gross Minority Interest |
|
29.54
-36.57%
|
46.56
-48.71%
|
90.78
|
| Total Capitalization |
|
34.81
-47.43%
|
66.21
-36.86%
|
104.87
|
| Working Capital |
|
22.17
-46.71%
|
41.59
-50.16%
|
83.45
|
| Invested Capital |
|
5.51
-91.68%
|
66.21
-37.22%
|
105.47
|
| Total Debt |
|
34.38
+60.45%
|
21.43
+23.70%
|
17.32
|
| Net Debt |
|
3.70
|
—
|
—
|
| Capital Lease Obligations |
|
29.11
+1537.29%
|
1.78
-32.42%
|
2.63
|
| Net Tangible Assets |
|
24.67
-17.19%
|
29.80
-59.76%
|
74.06
|
| Tangible Book Value |
|
-4.63
-115.53%
|
29.80
-59.76%
|
74.06
|
| Derivative Product Liabilities |
|
0.04
-90.19%
|
0.37
+239.81%
|
0.11
|
| Preferred Stock Equity |
|
29.30
|
—
|
—
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-34.67
+10.46%
|
-38.72
-5.50%
|
-36.70
|
| Cash Flow From Continuing Operating Activities |
|
-34.67
+10.46%
|
-38.72
-5.50%
|
-36.70
|
| Net Income From Continuing Operations |
|
-47.72
+1.54%
|
-48.47
-24.42%
|
-38.96
|
| Depreciation Amortization Depletion |
|
4.10
+42.68%
|
2.88
+82.66%
|
1.57
|
| Depreciation |
|
3.59
+51.99%
|
2.36
+111.47%
|
1.12
|
| Amortization Cash Flow |
|
0.52
+0.00%
|
0.52
+12.45%
|
0.46
|
| Depreciation And Amortization |
|
4.10
+42.68%
|
2.88
+82.66%
|
1.57
|
| Amortization Of Intangibles |
|
0.52
+0.00%
|
0.52
+12.45%
|
0.46
|
| Other Non Cash Items |
|
0.77
+58.71%
|
0.48
+44.74%
|
0.33
|
| Stock Based Compensation |
|
3.96
+6.33%
|
3.73
+243.19%
|
1.09
|
| Provisionand Write Offof Assets |
|
1.20
+249.27%
|
0.34
|
—
|
| Asset Impairment Charge |
|
11.63
|
0.00
|
0.00
|
| Operating Gains Losses |
|
-0.20
-127.05%
|
0.72
-68.71%
|
2.30
|
| Gain Loss On Investment Securities |
|
-0.33
-4037.50%
|
-0.01
-100.48%
|
1.66
|
| Gain Loss On Sale Of PPE |
|
0.14
+6700.00%
|
0.00
|
—
|
| Change In Working Capital |
|
-7.77
-534.58%
|
1.79
+158.84%
|
-3.04
|
| Change In Receivables |
|
-1.33
+47.33%
|
-2.53
-244.08%
|
-0.73
|
| Changes In Account Receivables |
|
-1.33
+47.33%
|
-2.53
-244.08%
|
-0.73
|
| Change In Inventory |
|
-1.82
-1186.31%
|
0.17
+111.49%
|
-1.46
|
| Change In Prepaid Assets |
|
2.52
+268.18%
|
0.69
+117.49%
|
-3.92
|
| Change In Payables And Accrued Expense |
|
-3.29
-382.46%
|
1.16
-73.53%
|
4.39
|
| Change In Other Working Capital |
|
-3.67
-197.94%
|
3.74
+790.77%
|
-0.54
|
| Change In Other Current Liabilities |
|
-0.18
+87.60%
|
-1.44
-86.08%
|
-0.78
|
| Investing Cash Flow |
|
-5.74
+68.10%
|
-18.01
-19.73%
|
-15.04
|
| Cash Flow From Continuing Investing Activities |
|
-5.74
+68.10%
|
-18.01
-19.73%
|
-15.04
|
| Net PPE Purchase And Sale |
|
-1.96
+56.04%
|
-4.47
-140.99%
|
-1.85
|
| Purchase Of PPE |
|
-1.98
+55.68%
|
-4.47
-140.99%
|
-1.85
|
| Sale Of PPE |
|
0.02
|
0.00
|
—
|
| Capital Expenditure |
|
-1.98
+55.68%
|
-4.47
-140.99%
|
-1.85
|
| Net Investment Purchase And Sale |
|
-3.78
+70.89%
|
-12.98
|
0.00
|
| Purchase Of Investment |
|
-33.77
+56.38%
|
-77.43
|
0.00
|
| Sale Of Investment |
|
30.00
-53.46%
|
64.44
|
0.00
|
| Net Business Purchase And Sale |
|
0.00
+100.00%
|
-0.56
+95.78%
|
-13.19
|
| Purchase Of Business |
|
0.00
+100.00%
|
-0.56
+95.78%
|
-13.19
|
| Financing Cash Flow |
|
11.56
+156.43%
|
4.51
-96.28%
|
121.08
|
| Cash Flow From Continuing Financing Activities |
|
11.56
+156.43%
|
4.51
-96.28%
|
121.08
|
| Net Issuance Payments Of Debt |
|
-15.09
-422.34%
|
4.68
-52.18%
|
9.79
|
| Issuance Of Debt |
|
0.00
-100.00%
|
19.76
+32.87%
|
14.87
|
| Repayment Of Debt |
|
-15.09
-0.09%
|
-15.08
-196.77%
|
-5.08
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
19.76
+32.87%
|
14.87
|
| Long Term Debt Payments |
|
-15.09
-0.09%
|
-15.08
-196.77%
|
-5.08
|
| Net Long Term Debt Issuance |
|
-15.09
-422.34%
|
4.68
-52.18%
|
9.79
|
| Net Common Stock Issuance |
|
—
|
0.00
-100.00%
|
112.48
|
| Proceeds From Stock Option Exercised |
|
8.25
+1321.90%
|
0.58
+235.26%
|
0.17
|
| Net Other Financing Charges |
|
—
|
-0.75
+44.99%
|
-1.37
|
| Changes In Cash |
|
-28.85
+44.75%
|
-52.21
-175.30%
|
69.34
|
| Beginning Cash Position |
|
30.59
-63.05%
|
82.81
+515.06%
|
13.46
|
| End Cash Position |
|
1.75
-94.30%
|
30.59
-63.05%
|
82.81
|
| Free Cash Flow |
|
-36.65
+15.14%
|
-43.18
-12.01%
|
-38.55
|
| Interest Paid Supplemental Data |
|
2.23
+61.86%
|
1.38
+67.15%
|
0.82
|
| Income Tax Paid Supplemental Data |
|
0.02
|
0.00
|
—
|
| Amortization Of Securities |
|
-0.64
-259.22%
|
-0.18
|
0.00
|
| Common Stock Issuance |
|
—
|
0.00
-100.00%
|
112.48
|
| Issuance Of Capital Stock |
|
18.41
|
0.00
-100.00%
|
112.48
|
| Net Preferred Stock Issuance |
|
18.41
|
0.00
|
—
|
| Other Cash Adjustment Inside Changein Cash |
|
-0.00
|
0.00
|
—
|
| Preferred Stock Issuance |
|
18.41
|
0.00
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|